Wet AMD pipeline: most promising candidates

adPEDF.11: Gene therapy, intravitreal injection, phase I

AGN211745: siRNA, intravitreal injection, phase II

Zybrestat: vascular disrupting agent, topical, animal studies

Sirolimus: Multi-mechanism, Subconjunctival or intravitreal injection or oral, phase II

ATG003: nAChR antagonist, topical , phase II

Avastin^® and Lucentis®: anti-VEGF, intravitreal injection, available

Macugen^®: anti-VEGF, intravitreal injection, available

VEGF Trap: VEGF receptor decoy, intravitreal injection, phase III

Vatalanib: Tyrosine kinase inhibitor, oral, phase II

Pazopanib: Tyrosine kinase inhibitor, , topical , phase II

TG101095 / TG100801: Tyrosine kinase inhibitor, topical, phase II

AL-39324: Tyrosine kinase inhibitor, intravitreal injection, animal studies

AG013958: Tyrosine kinase inhibitor, subtenon injection, animal studies

JSM6427: integrin antagonist, intravitreal injection, phase I

PF-04523655 (REDD14NP) Wet AMD; phase I (Quark/Pfizer)